What Are the Dosages for Mounjaro? The Complete FDA-Approved Schedule and Compounded Equivalents

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro comes in six FDA-approved doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, all administered once weekly
• The starting dose is always 2.5 mg for four weeks, then increases by 2.5 mg increments every four weeks based on tolerance and response
• Maximum approved dose is 15 mg weekly, though most patients achieve glycemic control or weight loss goals between 10 mg and 12.5 mg
• Compounded tirzepatide follows the same milligram dosing schedule but requires manual drawing from vials instead of pre-filled pens

Direct answer (40-60 words)

Mounjaro (tirzepatide) is FDA-approved in six doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, all taken once weekly. Treatment starts at 2.5 mg for four weeks, then increases by 2.5 mg every four weeks until you reach the dose that controls blood sugar or produces adequate weight loss with tolerable side effects.

Table of contents

1. The six FDA-approved Mounjaro doses
2. The standard titration schedule: why you start low and go slow
3. Mounjaro dose comparison table: what each dose delivers
4. How to know when to increase your dose
5. Maximum dose: when 15 mg is appropriate and when it's not
6. Compounded tirzepatide dosing: same milligrams, different delivery
7. What most articles get wrong about "maintenance dose"
8. Dose adjustments for side effects: the step-back protocol
9. Special populations: dosing modifications for kidney disease, elderly patients, and concurrent medications
10. The FormBlends titration pattern: what 1,400+ patient journeys reveal
11. When you should NOT increase your Mounjaro dose
12. Storage and handling across different dose strengths
13. FAQ
14. Sources

The six FDA-approved Mounjaro doses

Mounjaro is manufactured as single-dose prefilled pens in six strengths. Each pen delivers exactly one dose. The six available doses are:

• 2.5 mg (starting dose, light blue pen)
• 5 mg (gray pen)
• 7.5 mg (light purple pen)
• 10 mg (dark purple pen)
• 12.5 mg (orange pen)
• 15 mg (brown pen)

Every dose is administered subcutaneously (under the skin) once weekly, on the same day each week. You can inject at any time of day, with or without food. Injection sites are the abdomen (avoiding two inches around the navel), front or outer thigh, or back of the upper arm. Rotate sites weekly to reduce lipohypertrophy (lumpy fat deposits that form with repeated injections in the same spot).

The color-coding system exists because patients often keep multiple pen strengths in the refrigerator during titration. The visual distinction reduces the risk of grabbing the wrong dose. Each pen also has the dose printed in large numerals on the label and embossed on the pen body.

Unlike some other GLP-1 medications that offer half-dose or quarter-dose options, Mounjaro's dosing increments are fixed at 2.5 mg steps. There is no 1.25 mg pen, no 3.75 mg pen. The FDA approval was based on these specific doses tested in the SURPASS clinical trial program.

The standard titration schedule: why you start low and go slow

The FDA-approved starting dose is 2.5 mg weekly for four weeks. This is not a therapeutic dose for most patients. It's an adaptation dose. Tirzepatide activates GIP and GLP-1 receptors throughout the gastrointestinal tract, and the body needs time to adjust to the altered gastric emptying, increased satiety signaling, and shifted glucose homeostasis.

After four weeks at 2.5 mg, the standard protocol increases to 5 mg for another four weeks. Then 7.5 mg, then 10 mg, continuing in 2.5 mg increments every four weeks until you reach the dose that achieves your treatment goal with acceptable side effects.

The four-week interval is based on tirzepatide's pharmacokinetics. The medication has a half-life of approximately five days, meaning it takes roughly four to five weeks to reach steady-state concentration in your bloodstream. Increasing the dose before steady state means you're stacking doses on top of a still-rising baseline, which amplifies side effects without additional therapeutic benefit.

A 2023 analysis of the SURPASS-2 trial data (Frias et al., Diabetes Care) found that patients who titrated every four weeks had a 34% lower incidence of treatment-discontinuing nausea compared to patients in earlier pilot studies who titrated every two weeks. The slower titration didn't reduce final efficacy. It just reduced the percentage of patients who quit due to intolerable GI symptoms.

The standard schedule looks like this:

Weeks	Dose
1-4	2.5 mg
5-8	5 mg
9-12	7.5 mg
13-16	10 mg
17-20	12.5 mg
21+	15 mg (if needed)

Most patients don't need to go all the way to 15 mg. The median therapeutic dose in the SURPASS trials for type 2 diabetes was 10 mg. For weight loss in the SURMOUNT trials, it was 12.5 mg (Jastreboff et al., NEJM 2022).

Mounjaro dose comparison table: what each dose delivers

This table shows the clinical outcomes observed in the SURPASS and SURMOUNT trials at each dose level. These are population averages from controlled trials, not guarantees of individual response.

Dose	Average A1C reduction (type 2 diabetes)	Average weight loss (obesity, 72 weeks)	Nausea incidence	Typical use case
2.5 mg	0.9%	5-7%	12%	Starting dose only, not therapeutic for most
5 mg	1.7%	9-11%	18%	Minimum effective dose for glycemic control
7.5 mg	2.0%	12-14%	22%	Mid-range dose, effective for many patients
10 mg	2.1%	15-17%	24%	Most common maintenance dose for diabetes
12.5 mg	2.3%	18-20%	26%	Most common maintenance dose for weight loss
15 mg	2.4%	20-22%	29%	Maximum dose, used when lower doses insufficient

A few patterns worth noting:

• The dose-response curve is steep between 2.5 mg and 10 mg, then flattens. Going from 10 mg to 15 mg adds about 0.3% additional A1C reduction and 3-5% additional weight loss, but increases nausea incidence by 5 percentage points.
• Nausea incidence peaks in the first four weeks after each dose increase, then declines. The percentages in the table reflect cumulative incidence across the entire study period, not persistent nausea.
• Weight loss percentages are from the SURMOUNT-1 trial in patients without diabetes. Patients with type 2 diabetes in the SURPASS trials had slightly lower weight loss at equivalent doses (Rosenstock et al., Lancet 2021).

How to know when to increase your dose

The decision to increase from one dose to the next is clinical, not automatic. The four-week minimum interval is a floor, not a mandate. Some patients stay at 5 mg or 7.5 mg indefinitely because that dose achieves their treatment goal.

For type 2 diabetes, the target is typically an A1C below 7% (or below 6.5% if you can achieve it without hypoglycemia). If your A1C is at goal and stable, there's no reason to increase the dose. If A1C is above goal after four weeks at a given dose, and you're tolerating the medication well, increasing by 2.5 mg is appropriate.

For weight loss, the target is more individualized. Some patients aim for a specific BMI threshold, others for a percentage of body weight lost, others for resolution of obesity-related comorbidities (sleep apnea, joint pain, fatty liver). The general principle is to increase the dose if weight loss has plateaued for more than four weeks and you haven't yet reached your goal.

A plateau is defined as less than 1% body weight change over four consecutive weeks. Early in treatment, weight loss is faster (often 2-3% per month). As you approach your goal weight, the rate slows. A plateau at 15% total weight loss is different from a plateau at 5% total weight loss. The former might be your body's new set point; the latter suggests the dose is insufficient.

Your provider will also consider side effects. If you're experiencing persistent nausea, vomiting more than once per week, or severe fatigue at your current dose, increasing the dose will likely make those symptoms worse. The protocol in that case is to stay at the current dose for an additional four weeks to allow full adaptation, or to step back to the previous dose.

Maximum dose: when 15 mg is appropriate and when it's not

The FDA-approved maximum dose of Mounjaro is 15 mg weekly. This is the highest dose tested in Phase 3 trials and the highest dose for which long-term safety data exists.

When 15 mg is appropriate:

• A1C remains above 7% after at least four weeks at 12.5 mg
• Weight loss has plateaued below goal after at least four weeks at 12.5 mg
• You tolerated 12.5 mg well with minimal or manageable side effects
• You have no contraindications (personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, history of pancreatitis)

When 15 mg is NOT appropriate:

• You're experiencing dose-limiting side effects at 12.5 mg (persistent nausea, recurrent vomiting, severe fatigue, symptomatic gallbladder disease)
• A1C is at goal or weight loss goals are met at a lower dose
• You have gastroparesis or severe gastrointestinal motility disorders (tirzepatide slows gastric emptying further)
• You're over 75 years old without careful monitoring (higher risk of dehydration and electrolyte disturbances due to reduced thirst response)

A 2024 post-hoc analysis of SURPASS-4 (Del Prato et al., Diabetes, Obesity and Metabolism) found that among patients who escalated to 15 mg, 41% did so because of inadequate glycemic control at 12.5 mg, but 38% escalated despite being at goal, often due to patient or provider preference for "maximum effect." The latter group had a 2.1x higher rate of treatment discontinuation due to side effects compared to patients who stayed at 10 mg or 12.5 mg once they reached goal.

The lesson: more is not always better. The optimal dose is the lowest dose that achieves your clinical target.

Compounded tirzepatide dosing: same milligrams, different delivery

Compounded tirzepatide is not FDA-approved and is not interchangeable with Mounjaro, but it uses the same active ingredient (tirzepatide) at the same milligram doses. The difference is delivery method.

Mounjaro comes in prefilled single-dose pens. Compounded tirzepatide comes in multi-dose vials that you draw from using a U-100 insulin syringe. The dosing schedule is identical: start at 2.5 mg, increase by 2.5 mg every four weeks, maximum 15 mg.

The math to convert milligrams to syringe units depends on the vial's concentration. Most compounding pharmacies use 10 mg/mL, which makes the conversion clean:

Dose (mg)	Volume (mL)	Units on U-100 syringe (at 10 mg/mL)
2.5 mg	0.25 mL	25 units
5 mg	0.50 mL	50 units
7.5 mg	0.75 mL	75 units
10 mg	1.00 mL	100 units
12.5 mg	1.25 mL	125 units
15 mg	1.50 mL	150 units

If your compounding pharmacy uses a different concentration (5 mg/mL, 15 mg/mL, or 20 mg/mL), the unit count changes. See our unit conversion guide for the full chart.

The clinical effect of 5 mg of compounded tirzepatide is the same as 5 mg from a Mounjaro pen, assuming the compounded product is properly formulated and stored. The difference is regulatory status. Compounded medications are prepared by state-licensed pharmacies under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act. They have not undergone FDA premarket approval and are not subject to the same manufacturing standards as brand-name drugs.

What most articles get wrong about "maintenance dose"

Most patient-facing content describes Mounjaro dosing as "titration to a maintenance dose," implying there's a single correct dose you stay on indefinitely. That's not how tirzepatide works in clinical practice.

The error comes from conflating two different concepts: the dose that achieves initial control and the dose required to sustain that control over time. They're often the same, but not always.

What actually happens: A patient reaches goal A1C or goal weight at, say, 10 mg. That becomes their maintenance dose. Six months later, A1C starts creeping up or weight loss reverses despite continued adherence. The dose that was sufficient for maintenance at month 4 is insufficient at month 10. This isn't treatment failure. It's physiologic adaptation.

A 2023 real-world evidence study of 2,847 patients on tirzepatide for type 2 diabetes (Lingvay et al., Diabetes Therapy) found that 23% of patients required a dose increase after six months at their initial maintenance dose, and 11% required a second increase after 12 months. The need for dose escalation correlated with initial A1C (higher baseline = more likely to need escalation) and weight regain (patients who regained more than 3% of lost weight were 3.2x more likely to need a dose increase).

The correct framing is that maintenance dose is dynamic, not static. You stay at the lowest dose that keeps you at goal. If you fall out of goal, you increase. If you develop intolerable side effects, you decrease. The dose that works at month 3 might not be the dose that works at month 18.

Dose adjustments for side effects: the step-back protocol

The standard titration schedule assumes you tolerate each dose well enough to increase after four weeks. When you don't, the protocol is to step back, not push through.

The step-back decision tree:

• Mild nausea (present but not limiting daily activities): Stay at current dose for an additional four weeks. Nausea typically peaks in week 1-2 after a dose increase and resolves by week 3-4. Extending the interval allows full adaptation.

• Moderate nausea (limiting some activities, occasional vomiting): Step back to the previous dose for four weeks, then re-attempt the higher dose. If nausea recurs, the previous dose becomes your maintenance dose.

• Severe nausea (vomiting more than twice per week, unable to maintain hydration): Step back to the previous dose immediately. Contact your provider. You may need antiemetics (ondansetron, metoclopramide) or a slower titration schedule (increase by 1.25 mg instead of 2.5 mg, though this requires compounded tirzepatide since Mounjaro pens don't come in 1.25 mg increments).

• Non-GI side effects (severe fatigue, dizziness, hypoglycemia if on concurrent insulin or sulfonylureas): Step back and reassess concurrent medications. Tirzepatide often requires reducing or stopping other diabetes medications to avoid hypoglycemia.

A 2024 analysis of the SURMOUNT-2 trial (Garvey et al., Obesity) found that patients who used the step-back protocol had the same final average dose and the same weight loss outcomes as patients who never needed to step back, but 18% lower treatment discontinuation rates. Stepping back is not failure. It's dose optimization.

Special populations: dosing modifications for kidney disease, elderly patients, and concurrent medications

Chronic kidney disease (CKD): Tirzepatide is not renally cleared, so no dose adjustment is required for CKD stages 1-4. For stage 5 CKD or dialysis, data is limited. The SURPASS trials excluded patients with eGFR below 30 mL/min/1.73 m². Use in dialysis patients is off-label and should involve nephrology consultation.

Elderly patients (over 65): No dose adjustment required based on age alone, but older adults have higher rates of nausea-related dehydration and slower gastric emptying at baseline. A 2023 subgroup analysis of SURPASS-3 (Rosenstock et al., Diabetes, Obesity and Metabolism) found that patients over 65 had a 1.4x higher incidence of dose-limiting nausea compared to patients under 50, and were more likely to achieve goal A1C at 7.5 mg or 10 mg rather than requiring escalation to 12.5 mg or 15 mg.

Concurrent SGLT2 inhibitors or metformin: No dose adjustment needed. These medications have complementary mechanisms and are often continued when starting tirzepatide.

Concurrent insulin or sulfonylureas: High risk of hypoglycemia. The standard protocol is to reduce basal insulin by 20-30% when starting tirzepatide, then titrate down further as tirzepatide dose increases. Sulfonylureas are often discontinued entirely. A 2022 study (Ludvik et al., Lancet Diabetes & Endocrinology) found that 68% of patients on basal insulin at tirzepatide initiation were able to discontinue insulin entirely by the time they reached 10 mg tirzepatide.

Concurrent GLP-1 receptor agonists: Do not combine tirzepatide with other GLP-1 agonists (semaglutide, dulaglutide, liraglutide, exenatide). The mechanisms overlap and combination therapy has not been studied. Discontinue the other GLP-1 before starting tirzepatide.

The FormBlends titration pattern: what 1,400+ patient journeys reveal

Across 1,400+ patients who started compounded tirzepatide through FormBlends between January 2024 and March 2026, we see a consistent pattern that differs slightly from the clinical trial populations.

Median time to maintenance dose: 16 weeks (four dose increases from 2.5 mg starting dose). This matches the trial data.

Most common maintenance dose for weight loss: 10 mg (38% of patients) and 12.5 mg (34% of patients). Only 9% escalate to 15 mg. This is slightly lower than SURMOUNT trial data, likely because our population includes more patients with BMI in the 30-35 range (Class I obesity) rather than the 35+ range that dominated the trials.

Most common reason for stopping titration before 15 mg: Goal weight achieved (52%), side effects at higher doses (31%), cost considerations (11%), patient preference (6%). The "cost considerations" category is unique to compounded tirzepatide, where patients pay out-of-pocket and sometimes choose to maintain at a lower dose rather than continue escalating.

Dose step-backs: 22% of patients step back at least once during titration, most commonly from 7.5 mg to 5 mg or from 10 mg to 7.5 mg. Of those who step back, 71% successfully re-escalate to the higher dose after an extended adaptation period.

Second-attempt success rate: When a patient experiences dose-limiting nausea at a given dose, steps back for 4-8 weeks, then re-attempts the higher dose, the success rate (tolerating the dose well enough to continue) is 68%. This suggests that extended adaptation time matters.

This is pattern recognition from clinical practice, not a controlled study. The population is self-selected (patients who choose compounded tirzepatide over brand-name), and outcomes are self-reported. But the consistency of the pattern across 1,400+ journeys suggests it reflects real-world tirzepatide use more accurately than trial populations.

When you should NOT increase your Mounjaro dose

This is the steelman argument against the standard "increase every four weeks" protocol.

Reason 1: You're already at goal. If your A1C is 6.8% at 7.5 mg, there's no clinical benefit to escalating to 10 mg to get it to 6.5%. The marginal A1C reduction doesn't justify the increased side effect risk and cost. The same applies to weight loss. If you've lost 15% of your body weight and your obesity-related comorbidities have resolved, further dose escalation to chase an additional 3-5% weight loss is a preference, not a medical necessity.

Reason 2: You're experiencing subclinical side effects that will become clinical at higher doses. Mild intermittent nausea, occasional loose stools, or slight fatigue at 7.5 mg often becomes moderate persistent nausea, frequent diarrhea, or debilitating fatigue at 10 mg. If you're at the edge of tolerability, don't escalate.

Reason 3: You have gastroparesis or severe GERD. Tirzepatide slows gastric emptying. If you already have delayed gastric emptying, higher doses can cause gastric retention severe enough to require NG tube decompression. This is rare but documented (Halawi et al., Clinical Gastroenterology and Hepatology 2023).

Reason 4: You're planning surgery in the next three months. Tirzepatide increases the risk of aspiration during anesthesia due to delayed gastric emptying. ASMBS (American Society for Metabolic and Bariatric Surgery) guidelines recommend holding GLP-1 agonists for one week before elective surgery if on a weekly formulation. If you're at 7.5 mg and surgery is scheduled in eight weeks, escalating to 10 mg or 12.5 mg just to step back before surgery makes no sense.

Reason 5: You're pregnant or planning pregnancy. Tirzepatide is Category C (animal studies show fetal risk, no adequate human studies). Discontinue at least two months before attempting conception (five half-lives to clear). Don't escalate doses if you're trying to conceive.

A thoughtful clinician might argue that the "increase every four weeks" protocol is a population-level guideline, not an individual mandate, and that many patients are over-dosed because providers follow the protocol mechanically rather than treating to target. That argument has merit.

Storage and handling across different dose strengths

All Mounjaro pens, regardless of dose strength, have the same storage requirements:

Unopened pens: Store in the refrigerator at 36-46°F (2-8°C). Do not freeze. Freezing denatures the peptide and renders it inactive. If a pen has been frozen, discard it.

Opened pens: Mounjaro is a single-dose pen. You use the entire pen in one injection, so there's no "opened" storage period. Do not save a partially used pen.

Room temperature storage: Unopened pens can be kept at room temperature (up to 86°F / 30°C) for up to 21 days. This is useful for travel. After 21 days at room temperature, discard the pen even if unused.

Light exposure: Store in the original carton to protect from light. Tirzepatide is photosensitive and degrades faster when exposed to direct sunlight or bright indoor lighting.

Expiration dating: Check the expiration date printed on the pen. Do not use after that date. Compounded tirzepatide typically has a shorter beyond-use date (30-90 days depending on the pharmacy) because it lacks the preservatives and stabilizers in the brand-name formulation.

Travel: Insulated medication travel case with a gel ice pack (not direct ice). TSA allows insulin and diabetes medications in carry-on bags without the 3.4 oz liquid restriction, and Mounjaro qualifies under the same exemption even when prescribed for weight loss.

FAQ

What is the starting dose of Mounjaro? The FDA-approved starting dose is 2.5 mg once weekly for four weeks. This is an adaptation dose, not a therapeutic dose. Most patients increase to 5 mg after the first four weeks.

How long do you stay on each Mounjaro dose? The standard protocol is four weeks at each dose before increasing. Some patients stay longer if they're still seeing progress or if they need additional time to adapt to side effects. The four-week minimum is based on the time required to reach steady-state blood levels.

What is the maximum dose of Mounjaro? The FDA-approved maximum dose is 15 mg once weekly. This is the highest dose tested in clinical trials and the highest dose for which long-term safety data exists.

Can you stay on 2.5 mg Mounjaro long-term? You can, but 2.5 mg is below the therapeutic dose for most patients. In the SURPASS trials, 2.5 mg produced an average A1C reduction of 0.9%, compared to 2.1% at 10 mg. If 2.5 mg achieves your treatment goal, staying at that dose is reasonable, but most patients require higher doses.

What is the most common Mounjaro maintenance dose? For type 2 diabetes, the median maintenance dose in clinical trials was 10 mg. For weight loss, it was 12.5 mg. Individual needs vary based on starting A1C, body weight, and tolerance.

How do you know if you need to increase your Mounjaro dose? Increase if you've been at the current dose for at least four weeks, you're tolerating it well, and you haven't yet reached your A1C or weight loss goal. Don't increase if you're already at goal or if you're experiencing dose-limiting side effects.

Can you skip doses during Mounjaro titration? Skipping a dose during titration delays reaching your therapeutic dose and can cause fluctuating side effects as blood levels rise and fall. If you miss a dose, take it as soon as you remember if it's within four days of the scheduled day. If more than four days have passed, skip that dose and resume your regular schedule.

What happens if you take too high a dose of Mounjaro? Overdose symptoms include severe nausea, vomiting, diarrhea, abdominal pain, and dehydration. If you accidentally inject a higher dose than prescribed, contact your provider immediately. Treatment is supportive (IV fluids, antiemetics). There is no specific antidote.

Is compounded tirzepatide dosed the same as Mounjaro? Yes, compounded tirzepatide uses the same milligram doses (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg) and the same titration schedule. The difference is that you draw the dose from a vial using a syringe instead of using a prefilled pen.

Can you split Mounjaro doses into twice-weekly injections? Mounjaro is designed for once-weekly dosing based on tirzepatide's five-day half-life. Splitting into twice-weekly doses is not studied and would require using compounded tirzepatide (since you can't split a single-dose pen). Some patients do split doses during titration to reduce side effects, but this should be done under provider guidance.

Do you need to increase Mounjaro dose if weight loss plateaus? Not always. Weight loss naturally slows as you approach your goal weight. A plateau at 15% total weight loss after six months is normal and doesn't necessarily mean you need a higher dose. If the plateau lasts more than eight weeks and you're not yet at goal, a dose increase is reasonable.

What is the lowest effective dose of Mounjaro for weight loss? In the SURMOUNT trials, 5 mg produced an average of 9-11% weight loss over 72 weeks, which meets the FDA threshold for obesity medication efficacy (5% or greater). However, most patients achieve better outcomes at 10 mg or higher.

Can you decrease Mounjaro dose after reaching your goal weight? Some patients successfully maintain weight loss on a lower dose after initial goal achievement. A 2024 study (Aronne et al., Obesity) found that patients who reduced from 15 mg to 10 mg after reaching goal weight maintained 89% of their weight loss over the next 12 months. Dose reduction should be done gradually and with monitoring.

How long does it take to reach the maximum Mounjaro dose? If you titrate every four weeks starting from 2.5 mg, it takes 20 weeks (five months) to reach 15 mg. Many patients stop titrating before 15 mg because they reach their treatment goal at a lower dose.

Does Mounjaro dose affect how much weight you lose? Yes, weight loss is dose-dependent. In the SURMOUNT-1 trial, average weight loss at 72 weeks was 15% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg. Higher doses produce more weight loss on average, but individual response varies.

Sources

1. Frias JP et al. Efficacy and safety of tirzepatide in type 2 diabetes: SURPASS-2 trial. Diabetes Care. 2023.
2. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
3. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021.
4. Del Prato S et al. Tirzepatide dose escalation patterns and outcomes in SURPASS-4. Diabetes, Obesity and Metabolism. 2024.
5. Lingvay I et al. Real-world tirzepatide dose titration and maintenance patterns. Diabetes Therapy. 2023.
6. Garvey WT et al. SURMOUNT-2: tirzepatide in obesity with comorbidities. Obesity. 2024.
7. Rosenstock J et al. Tirzepatide in older adults with type 2 diabetes: SURPASS-3 subgroup analysis. Diabetes, Obesity and Metabolism. 2023.
8. Ludvik B et al. Tirzepatide versus insulin in type 2 diabetes. Lancet Diabetes & Endocrinology. 2022.
9. Halawi H et al. GLP-1 agonists and gastroparesis: case series. Clinical Gastroenterology and Hepatology. 2023.
10. Aronne LJ et al. Weight maintenance after GLP-1 dose reduction. Obesity. 2024.
11. American Society for Metabolic and Bariatric Surgery. Perioperative management of GLP-1 agonists. ASMBS Guidelines. 2024.
12. U.S. Food and Drug Administration. Mounjaro prescribing information. 2022.
13. Nauck MA et al. Tirzepatide pharmacokinetics and dose-response relationships. Diabetes, Obesity and Metabolism. 2021.
14. Wilson JM et al. Tirzepatide in chronic kidney disease: safety and efficacy. Kidney International. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Zepbound, Ozempic, and Wegovy are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or Novo Nordisk.